Version 1
: Received: 27 February 2024 / Approved: 27 February 2024 / Online: 28 February 2024 (04:48:26 CET)
How to cite:
Manenti, G.; Perretta, T.; Nezzo, M.; Fraioli, F. R.; Carreri, B.; Gigliotti, P. E.; Micillo, A.; Malizia, A.; Di Giovanni, D.; Ryan, C. P.; Garaci, F. G. TransPerineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer. Preprints2024, 2024021578. https://doi.org/10.20944/preprints202402.1578.v1
Manenti, G.; Perretta, T.; Nezzo, M.; Fraioli, F. R.; Carreri, B.; Gigliotti, P. E.; Micillo, A.; Malizia, A.; Di Giovanni, D.; Ryan, C. P.; Garaci, F. G. TransPerineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer. Preprints 2024, 2024021578. https://doi.org/10.20944/preprints202402.1578.v1
Manenti, G.; Perretta, T.; Nezzo, M.; Fraioli, F. R.; Carreri, B.; Gigliotti, P. E.; Micillo, A.; Malizia, A.; Di Giovanni, D.; Ryan, C. P.; Garaci, F. G. TransPerineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer. Preprints2024, 2024021578. https://doi.org/10.20944/preprints202402.1578.v1
APA Style
Manenti, G., Perretta, T., Nezzo, M., Fraioli, F. R., Carreri, B., Gigliotti, P. E., Micillo, A., Malizia, A., Di Giovanni, D., Ryan, C. P., & Garaci, F. G. (2024). TransPerineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer. Preprints. https://doi.org/10.20944/preprints202402.1578.v1
Chicago/Turabian Style
Manenti, G., Colleen Patricia Ryan and Francesco Giuseppe Garaci. 2024 "TransPerineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer" Preprints. https://doi.org/10.20944/preprints202402.1578.v1
Abstract
Background: this interventional pilot study aimed to evaluate the short-term (3 years) efficacy of focal laser ablation (FLA) in treating the index lesion of low-intermediate risk prostate cancer, along with assessing the safety of the procedure (ClinicalTrials.gov ID NCT04045756). Methods: forty patients aged between 46 and 86 with histologically proven organ-confined prostate cancer and low to intermediate progression risk were included. FLA was performed under percutaneous fusion magnetic resonance/ultrasound guidance in a Day Hospital setting under local anesthesia. Patients underwent regular clinical assessments, PSA measurements, post-procedure MRI scans, and biopsies at 36 months or if positive findings were detected earlier. Statistical analyses were conducted to assess trends in PSA levels and cavity dimensions over time. Results: forty patients were initially included, with 15 lost to follow-up. At 36 months, a mean PSA reduction of 60% was observed, and 80% of MRI scans showed no signs of in-field clinically significant residual/recurrent cancer. Biopsies at 36 months revealed no malignant findings in 20 patients. No deterioration in sexual function or urinary symptoms was recorded. Conclusions: FLA appears to be safe, feasible and effective in the index lesion treatment of low-intermediate risk prostate cancer, with a high rate of tumor eradication and preservation of quality of life.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.